Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA …
网页2024年3月21日 — KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD- L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and...
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) …
网页2024年9月15日 — At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined …
网页2021年5月5日 — KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥10) as …
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
网页2023年11月16日 — Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone. Approval marks seventh gastrointestinal cancer indication for KEYTRUDA-based regimens and 38th indication for KEYTRUDA in the US.
Merck wins first FDA approval for Keytruda as a treatment for ...
网页2024年9月18日 — Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated...
Moderna, Merck cancer vaccine with Keytruda improved survival …
网页2024年6月3日 — The vaccine together with Merck’s Keytruda improved survival and showed long-lasting efficacy in a midstage study in patients with a deadly form of skin cancer. Moderna and Merck are presenting...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
网页2024年6月17日 — KEYTRUDA is now the first and only anti-PD-1 therapy FDA-approved in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial carcinoma regardless of mismatch repair status. Approval marks the third FDA-approved indication for KEYTRUDA in endometrial carcinoma and the 40 th indication for KEYTRUDA in the US
FDA approves pembrolizumab as adjuvant treatment for non …
网页On January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB...
Padcev and Keytruda Double Bladder Cancer Survival - NCI
网页2023年11月30日 — One treatment—the combination of enfortumab vedotin (Padcev) and the immunotherapy drug pembrolizumab (Keytruda) —proved to be particularly powerful. The findings mark a pivotal moment following years of little progress, according to several leading bladder cancer experts.
FDA approves pembrolizumab combination for the first-line …
网页On October 13,2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for patients with persistent,...